WATCH LIVE
timothy sykes logo
NMRA Slides As Neumora Axes Navacaprant After Phase 3 Failure Thumbnail
G Google News

NMRA Slides As Neumora Axes Navacaprant After Phase 3 Failure

JACK KELLOGG•UPDATED JUN. 27, 2026, 11:08 AM ET
Reviewed by Ellis Hobbsand Fact-checked by Matt Monaco

Neumora Therapeutics Inc. stocks have been trading up by 8.61 percent on strong sentiment from its latest neuroscience pipeline progress.

Market Insights For NMRA Traders

  • Phase 3 KOASTAL-2 and KOASTAL-3 navacaprant trials in major depressive disorder failed main endpoints, forcing Neumora Therapeutics Inc. to discontinue the program.
  • Following the navacaprant collapse, H.C. Wainwright slashed its NMRA price target from $18 to $7 while keeping a Buy rating focused on remaining assets.
  • Needham cut its target from $8 to $5 and flagged a 35% workforce reduction, with expected savings of about $10M per year as Neumora Therapeutics Inc. moves to protect cash.
  • Mizuho lowered its NMRA target from $6 to $4 after removing navacaprant, but still calls the early-stage pipeline attractive and rates the stock Outperform.
  • Even after these cuts, the NMRA analyst group remains overweight, with an average price target near $6.71, well above current trading levels.

Candlestick Chart

Weekly Update Jun 22 – Jun 26, 2026: On Saturday, June 27, 2026 Neumora Therapeutics Inc. stock [NASDAQ: NMRA] is trending up by 8.61%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – positive

Neumora Therapeutics (NMRA) is an early‑stage CNS biotech with no revenue, deeply negative profitability (ROE ~‑149%, ROA ~‑108%) and heavy R&D spend ($38.6M in Q1 2026 vs $14.3M G&A). Liquidity is strong near term: $147M cash, current ratio 5.1, and working capital of ~$123M, but quarterly operating cash burn of ~$46M implies ~7–8 quarters of runway absent further cuts. Leverage is modest (LT debt ~$53M, debt/equity 0.76) but book value per share is thin at $0.39 and priced at ~6.4x book.

Technically, NMRA is stabilizing after a capitulation phase post‑navacaprant failure. This week’s tape shows a constructive progression from $1.46–1.55 congestion to a close at $1.64, with higher highs and higher lows on incremental bid support. The dominant short‑term trend is a nascent uptrend off oversold levels. A key actionable level is $1.45–1.47; it should now act as support. Aggressive traders can buy dips above $1.45 with a tight stop below $1.40, targeting a near‑term move toward $1.90–2.00 as the first resistance zone.

Fundamentally, the stock has been reset after KOASTAL‑2/3 failure and navacaprant discontinuation, with a 35% workforce reduction targeting ~$10M annual savings. Street targets have been cut sharply (Mizuho to $4, Needham $5, H.C. Wainwright $7), yet ratings remain broadly Buy/Outperform, reflecting confidence in the early‑stage pipeline. Relative to healthcare and biotech benchmarks, NMRA is higher‑risk, higher‑beta and earlier stage. My verdict: speculative Buy for high‑risk investors, with $1.40 support, $2.00 resistance, and a 6–12 month upside target range of $3–4 assuming clean execution and no further clinical setbacks.

More Breaking News

Quick Financial Overview

Neumora Therapeutics Inc. is trading deep in the penalty box after its Phase 3 navacaprant program failed, with NMRA hovering around the mid-$1 range. The recent weekly data show closes between roughly $1.46 and $1.64, signaling a narrow but weak consolidation after a sharp repricing. Intraday, a 5-minute candle ranging from about $1.48 to $1.66 and closing near $1.64 shows that dip buyers are active, but only within a tight band.

Fundamentally, NMRA is a classic high-burn, clinical-stage biotech. The latest quarter shows net income of about -$53.5M and operating cash outflow near -$46.4M, with free cash flow also around -$46.4M. Yet Neumora Therapeutics Inc. holds roughly $147.1M in cash and a strong current ratio near 5.1, giving the company meaningful runway even after the navacaprant setback.

Valuation ratios highlight the speculative nature of NMRA. With a price-to-book near 6.38 and very negative returns on equity and assets, the current market cap is driven by optionality on the remaining pipeline, not earnings power. Leverage is moderate, with total debt-to-equity around 0.76, and the planned 35% workforce reduction aiming to save about $10M annually should help slow the cash bleed. For traders, this mix of ample cash, heavy losses, and lowered Street targets sets up a binary sentiment battleground.

Conclusion

NMRA is now a post-failure biotech reset story. The Phase 3 KOASTAL-2 and KOASTAL-3 misses wiped out navacaprant as a near-term driver, forcing Neumora Therapeutics Inc. to cut staff and refocus on earlier-stage assets. Price targets have been slashed across the board, with H.C. Wainwright dropping to $7, Needham to $5, and Mizuho to $4, yet all still keep positive ratings and the average target sits far above the roughly $1.50 trading area.

For short-term traders, that gap between current price and the $4–$7 target band is the core setup. The chart shows a tight base forming after heavy damage, with support developing in the mid-$1s and quick bounces toward $1.60–$1.65 when buyers step in. At the same time, the financials confirm NMRA remains a cash-burning, loss-making clinical platform whose value depends on unproven pipeline programs.

That combination means elevated risk but also room for sharp squeezes on any positive pipeline update or sentiment shift. Traders should treat Neumora Therapeutics Inc. as a speculative, event-driven vehicle, size positions conservatively, and respect downside if the base around $1.40–$1.50 fails. Risk management is crucial in this kind of volatile biotech setup; as millionaire penny stock trader and teacher Tim Sykes, says, “It’s better to go home at zero than to go home in the red.” As I tell my own students, “In names like NMRA, the edge comes from trading the reaction to catalysts, not from guessing long-term science outcomes.”

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”